Log in

Ovid Therapeutics News Headlines (NASDAQ:OVID)

$3.79
-0.03 (-0.79 %)
(As of 02/19/2020 04:27 AM ET)
Today's Range
$3.71
Now: $3.79
$3.97
50-Day Range
$3.38
MA: $3.83
$4.36
52-Week Range
$1.53
Now: $3.79
$5.24
Volume708,152 shs
Average Volume534,831 shs
Market Capitalization$181.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.86

Headlines

Ovid Therapeutics (NASDAQ OVID) News Headlines

Source:
DateHeadline
Ovid Therapeutics Inc (NASDAQ:OVID) Expected to Announce Earnings of -$0.43 Per ShareOvid Therapeutics Inc (NASDAQ:OVID) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 16 at 4:18 AM
Ovid Therapeutics Inc (NASDAQ:OVID) Short Interest Up 5.8% in JanuaryOvid Therapeutics Inc (NASDAQ:OVID) Short Interest Up 5.8% in January
www.americanbankingnews.com - February 15 at 3:26 AM
Ovid Therapeutics Inc (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from AnalystsOvid Therapeutics Inc (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 9:47 AM
Here Are Some Valentine’s Day Lessons From 43 BC Roman Poet OvidHere Are Some Valentine’s Day Lessons From 43 BC Roman Poet Ovid
www.forbes.com - February 5 at 7:29 PM
With strong work ethic and play, Justin Moore keying perfect start for Ovid-Elsie hoopsWith strong work ethic and play, Justin Moore keying perfect start for Ovid-Elsie hoops
www.msn.com - January 31 at 12:50 AM
Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 234.6%Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 234.6%
www.americanbankingnews.com - January 26 at 8:16 PM
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Invest In Growth?Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Invest In Growth?
finance.yahoo.com - January 10 at 5:17 PM
BRIEF-Ovid Therapeutics Provides Update On Multiple Clinical Data Readouts Across Rare Neurological Disease PlatformBRIEF-Ovid Therapeutics Provides Update On Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
www.msn.com - January 7 at 5:26 PM
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease PlatformOvid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
finance.yahoo.com - January 7 at 5:26 PM
Hedge Funds Have Never Been More Bullish On Ovid Therapeutics Inc. (OVID)Hedge Funds Have Never Been More Bullish On Ovid Therapeutics Inc. (OVID)
finance.yahoo.com - December 19 at 11:30 PM
Is Travelzoo Inc. (TZOO) A Good Stock To Buy?Is Travelzoo Inc. (TZOO) A Good Stock To Buy?
finance.yahoo.com - December 16 at 9:20 AM
RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020RBC: 3 “Strong Buy” Stocks That Could Step on the Gas in 2020
finance.yahoo.com - December 6 at 1:54 PM
RBC bullish on OVIDs 2020 catalystsRBC bullish on OVID's 2020 catalysts
seekingalpha.com - November 29 at 7:50 AM
Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare ConferenceOvid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 26 at 8:23 AM
Ovid Therapeutics Appoints Jason Tardio as Chief Commercial OfficerOvid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
finance.yahoo.com - November 18 at 8:26 PM
Ovid Therapeutics EPS misses by $0.06Ovid Therapeutics EPS misses by $0.06
seekingalpha.com - November 8 at 12:27 PM
Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent ProgressOvid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress
finance.yahoo.com - November 8 at 12:27 PM
Executives on the move at Ovid TherapeuticsExecutives on the move at Ovid Therapeutics
seekingalpha.com - November 1 at 2:03 PM
Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020
finance.yahoo.com - November 1 at 9:02 AM
Jeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On SharesJeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On Shares
finance.yahoo.com - October 12 at 1:29 PM
Ovid Therapeutics, Sunrun, Pure Cycle, and Other 13D FilingsOvid Therapeutics, Sunrun, Pure Cycle, and Other 13D Filings
finance.yahoo.com - October 11 at 10:33 PM
OVID Ovid Therapeutics Inc. Common StockOVID Ovid Therapeutics Inc. Common Stock
www.nasdaq.com - October 6 at 8:47 AM
Mid-Day Market Update: Dow Rises Over 200 Points; Ovid Therapeutics Shares PlungeMid-Day Market Update: Dow Rises Over 200 Points; Ovid Therapeutics Shares Plunge
www.benzinga.com - October 4 at 4:05 PM
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred StockOvid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
finance.yahoo.com - October 4 at 4:05 PM
Ovid -13% on common, preferred offeringsOvid -13% on common, preferred offerings
seekingalpha.com - October 3 at 5:08 PM
Will Ovid Therapeutics Continue to Surge Higher?Will Ovid Therapeutics Continue to Surge Higher?
finance.yahoo.com - September 24 at 5:33 PM
Ovid up 7% on positive soticlestat dataOvid up 7% on positive soticlestat data
seekingalpha.com - September 23 at 3:41 PM
Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare EpilepsiesOvid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
finance.yahoo.com - September 23 at 10:40 AM
Could The Ovid Therapeutics Inc. (NASDAQ:OVID) Ownership Structure Tell Us Something Useful?Could The Ovid Therapeutics Inc. (NASDAQ:OVID) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - September 21 at 12:28 AM
Ovid Therapeutics: High Risk/High RewardOvid Therapeutics: High Risk/High Reward
seekingalpha.com - September 16 at 12:33 PM
Enrollment underway in late-stage study of Ovids gaboxadol in AngelmanEnrollment underway in late-stage study of Ovid's gaboxadol in Angelman
seekingalpha.com - September 13 at 9:29 AM
Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceOvid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
finance.yahoo.com - September 9 at 8:49 AM
Ovid Therapeutics Announces Participation in Two Upcoming Investor ConferencesOvid Therapeutics Announces Participation in Two Upcoming Investor Conferences
finance.yahoo.com - September 3 at 10:49 AM
Metabolomics Biomarker Market to Receive Overwhelming Hike in Revenues by 2025Metabolomics Biomarker Market to Receive Overwhelming Hike in Revenues by 2025
www.marketwatch.com - August 27 at 5:59 PM
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent ProgressOvid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
finance.yahoo.com - August 7 at 5:16 PM
Ovid Therapeutics: Lack Of Clear Efficacy Signals Do Not Look ConvincingOvid Therapeutics: Lack Of Clear Efficacy Signals Do Not Look Convincing
seekingalpha.com - August 2 at 6:50 PM
Some Ovid Therapeutics (NASDAQ:OVID) Shareholders Have Taken A Painful 71% Share Price DropSome Ovid Therapeutics (NASDAQ:OVID) Shareholders Have Taken A Painful 71% Share Price Drop
finance.yahoo.com - July 9 at 5:21 PM
Ovid up 10% on advancement of OV101 in AngelmanOvid up 10% on advancement of OV101 in Angelman
seekingalpha.com - July 2 at 5:21 PM
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman SyndromeOvid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
finance.yahoo.com - July 2 at 9:47 AM
Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020
finance.yahoo.com - June 27 at 9:58 AM
Ovid Therapeutics to Host R&D Day on June 27, 2019Ovid Therapeutics to Host R&D Day on June 27, 2019
finance.yahoo.com - June 18 at 6:10 PM
BIO Elects Dr. Jeremy Levin as New Board ChairBIO Elects Dr. Jeremy Levin as New Board Chair
www.marketwatch.com - June 4 at 9:51 AM
Ovid Therapeutics to Present at the 12th International Epilepsy ColloquiumOvid Therapeutics to Present at the 12th International Epilepsy Colloquium
finance.yahoo.com - May 23 at 6:04 PM
Ovid Therapeutics: Multiple Ways To Win In This Beaten-Down BiotechOvid Therapeutics: Multiple Ways To Win In This Beaten-Down Biotech
seekingalpha.com - May 8 at 6:14 PM
Angelman syndromeAngelman syndrome
www.benzinga.com - May 7 at 9:41 AM
Ovid Therapeutics misses by $0.05Ovid Therapeutics misses by $0.05
seekingalpha.com - May 7 at 9:41 AM
Ovid Therapeutics Rallies On Rare Genetic Disorder Drug DataOvid Therapeutics Rallies On Rare Genetic Disorder Drug Data
finance.yahoo.com - May 7 at 9:41 AM
Ovid Therapeutics Reports First Quarter 2019 Financial ResultsOvid Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 7 at 9:41 AM
Ovid up 16% on OV101 data in rare inherited disordersOvid up 16% on OV101 data in rare inherited disorders
seekingalpha.com - May 6 at 9:48 AM
Have Insiders Been Buying Ovid Therapeutics Inc. (NASDAQ:OVID) Shares This Year?Have Insiders Been Buying Ovid Therapeutics Inc. (NASDAQ:OVID) Shares This Year?
finance.yahoo.com - April 27 at 4:39 PM
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel